Form 4: BridgeBio CFO Sells $2.09M in Company Stock

BridgeBio Pharma's President and CFO, Thomas Trimarchi, reported the sale of 42,237 shares of common stock for approximately $2.09 million.

Summary

• Thomas Trimarchi, President and Chief Financial Officer of BridgeBio Pharma, Inc. (BBIO), reported a transaction involving the company's common stock.
• He disposed of 42,237 shares of BBIO common stock on August 21, 2025.
• The shares were sold at a weighted average price of $49.4846 per share, with individual sale prices ranging from $49.08 to $49.77.
• This transaction was made pursuant to a Rule 10b5-1(c) plan.
• Following this sale, Mr. Trimarchi directly beneficially owns 421,081 shares of BridgeBio Pharma common stock.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive, even if pre-planned under a Rule 10b5-1 plan, can be perceived negatively by the market. However, the executive still retains a substantial stake, mitigating extreme bearishness.

Negatives

• The sale of a significant number of shares by a key executive, such as the President and CFO, can be perceived negatively by the market, potentially signaling a belief that the stock is fully valued or a lack of confidence.
• The transaction value of approximately $2.09 million represents a material disposition of equity by an insider.

Risks

• Potential negative market reaction or investor sentiment due to insider selling, which could lead to downward pressure on the stock price.
• Increased scrutiny from investors regarding management's long-term commitment and outlook for the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially leading to downward pressure on the stock price or increased investor caution.

Key Dates

Recommendation

While the sale of shares by the President and CFO, Thomas Trimarchi, could be viewed as a negative signal by the market, the transaction was executed pursuant to a pre-arranged Rule 10b5-1 plan, suggesting it was not based on new, adverse information. The executive also retains a substantial number of shares (421,081). Therefore, a 'hold' recommendation is appropriate, advising investors to monitor broader company performance and future developments rather than reacting solely to this single insider transaction.

Keywords

BridgeBio Pharma, BBIO, Insider Sale, Form 4, Thomas Trimarchi, CFO, President, Stock Transaction, Equity Sale, Biotechnology, Rule 10b5-1